- Home
- SNX vs BBIO Comparison
SNX vs BBIO Comparison
Compare SNX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- BBIO
- Stock Information
- Founded
- SNX 1980
- BBIO 2015
- Country
- SNX United States
- BBIO United States
- Employees
- SNX N/A
- BBIO N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- BBIO Health Care
- Exchange
- SNX Nasdaq
- BBIO Nasdaq
- Market Cap
- SNX 11.7B
- BBIO 9.4B
- IPO Year
- SNX 2003
- BBIO 2019
- Fundamental
- Price
- SNX $152.23
- BBIO $51.47
- Analyst Decision
- SNX Strong Buy
- BBIO Strong Buy
- Analyst Count
- SNX 10
- BBIO 16
- Target Price
- SNX $149.80
- BBIO $64.44
- AVG Volume (30 Days)
- SNX 520.4K
- BBIO 2.2M
- Earning Date
- SNX 09-25-2025
- BBIO 11-11-2025
- Dividend Yield
- SNX 1.15%
- BBIO N/A
- EPS Growth
- SNX 19.95
- BBIO N/A
- EPS
- SNX 8.55
- BBIO N/A
- Revenue
- SNX $60,007,297,000.00
- BBIO $235,812,000.00
- Revenue This Year
- SNX $4.71
- BBIO $115.97
- Revenue Next Year
- SNX $4.14
- BBIO $65.50
- P/E Ratio
- SNX $17.88
- BBIO N/A
- Revenue Growth
- SNX 6.60
- BBIO 7.62
- 52 Week Low
- SNX $92.23
- BBIO $21.72
- 52 Week High
- SNX $154.44
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- SNX 61.15
- BBIO 53.80
- Support Level
- SNX $150.95
- BBIO $52.20
- Resistance Level
- SNX $153.06
- BBIO $54.29
- Average True Range (ATR)
- SNX 2.21
- BBIO 2.21
- MACD
- SNX 0.14
- BBIO -0.16
- Stochastic Oscillator
- SNX 75.82
- BBIO 57.36
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.